Ketamine-induced cystitis resulting from long-term abuse: A case report

Le Ngoc Ha, Pham Thi Ngoc Bich, Nguyen Van Thanh, Cao Manh Long, Nguyen Thi Thu Hang, Ha Hong Cuong, Nguyen Minh Ha

Main Article Content

Abstract

Ketamine-induced cystitis (KIC) is a severe urological condition resulting from ketamine abuse, characterized by persistent lower urinary tract symptoms (LUTS), often misdiagnosed, and associated with irreversible bladder damage risk. We report a case of a 26-year-old woman with a 4-year history of ketamine abuse who presented with a 2-year history of complex LUTS, including urinary frequency (every 5 - 10 minutes), urgency, and suprapubic pain. She had no sign of tuberculosis, negative urine cultures, and no response to antibiotics. Computed tomography (CT) of the urinary tract revealed a small, diffusely thickened bladder wall (8mm) without obstruction. The patient was diagnosed with KIC and managed conservatively with ketamine cessation, pharmacologic therapy (neuropathic pain control and anticholinergics), and pelvic floor rehabilitation. After 10 days, her symptoms markedly improved, with voiding intervals increasing to 60 - 120 minutes and no withdrawal symptom observed. She was discharged and followed up as an outpatient. KIC should be considered in young patients with persistent LUTS; eliciting a history of substance abuse is essential for diagnosis, and cessation of ketamine use remains the cornerstone of treatment.

Article Details

References

1. Liang Y, Chen YP, Lin Z, et al. An updated review of the epidemiology, diagnosis, and treatment of ketamine-induced cystitis. Ther Adv Urol. 2024; 16: 17562872241232821.
2. Patel K, Kumar P, Batura D. Understanding and managing ketamine-associated uropathy. BJU Int. 2023; 132(1): 19-27.
3. Cohen D, McClain R, Tarry W, Gilleran J. A comprehensive review of treatment strategies for ketamine cystitis. Curr Urol Rep. 2023; 24(9): 487-495.
4. Zeng J, Lai H, Zheng D, et al. The current status of diagnosis and treatment for ketamine-induced cystitis. Int J Urol. 2021; 28(5): 482-488.
5. Fu Y, He C, Zhou Z, et al. Imaging findings in ketamine-induced uropathy: a systematic review. Front Psychiatry. 2022; 13: 985253.
6. Wang Z, Chen Z, Liu Z, et al. Pathophysiology of ketamine-induced cystitis: a review of recent experimental and clinical findings. J Inflamm Res. 2023; 16: 3541-3552.
7. Baker SC, Swift-Scanlan T, Ginzburg S, et al. Urothelial cell apoptosis and inflammation in ketamine-induced cystitis. Am J Clin Exp Urol. 2022; 10(1): 10-18.
8. Jhang JF, Hsu YH, Jiang YH. Advances in the diagnosis and treatment of ketamine-induced cystitis. Urol Sci. 2023; 34(2): 66-72.
9. Misra S, Chetwood A, Coker C, et al. Magnetic resonance imaging in the diagnosis and management of ketamine-induced uropathy. Urol Int. 2024; 108(2): 120-127.
10. Anderson DJ, Zhou J, Cao D, et al. Ketamine-induced cystitis: a comprehensive review of the urologic effects of this psychoactive drug. Health Psychol Res. 2022; 10(3): 38247. doi:10.52965/001c.38247.
11. Wang CC, Chuang YC, Lee WC, Chuang SM, Kuo HC. Long-term outcomes of augmentation enterocystoplasty in patients with ketamine-induced cystitis. Neurourol Urodyn. 2021; 40(3): 856-862. doi:10.1002/nau.24641.
12. Chu PS, Kwok JSS, Chan YC, et al. The impact of continued ketamine use on lower urinary tract symptoms and bladder functional capacity in patients with ketamine cystitis who had undergone augmentation enterocystoplasty. BJU Int. 2021; 127(4): 456-463. doi:10.1111/bju.15197.